The stock of Becton Dickinson & Co. (BDX) has seen a -0.90% decrease in the past week, with a -1.83% drop in the past month, and a -0.92% decrease in the past quarter. The volatility ratio for the week is 1.94%, and the volatility levels for the past 30 days are at 1.61% for BDX. The simple moving average for the last 20 days is -1.95% for BDX stock, with a simple moving average of -2.13% for the last 200 days.
Is It Worth Investing in Becton Dickinson & Co. (NYSE: BDX) Right Now?
Becton Dickinson & Co. (NYSE: BDX) has a price-to-earnings ratio of 47.65x that is above its average ratio. Additionally, the 36-month beta value for BDX is 0.44. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 7 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BDX is 288.63M and currently, short sellers hold a 0.69% ratio of that float. The average trading volume of BDX on September 19, 2024 was 1.37M shares.
BDX) stock’s latest price update
The stock price of Becton Dickinson & Co. (NYSE: BDX) has surged by 0.14 when compared to previous closing price of 231.27, but the company has seen a -0.90% decline in its stock price over the last five trading sessions. prnewswire.com reported 2024-09-18 that LE PONT-DE-CLAIX, France, Sept. 18, 2024 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak™ Glass Prefillable Syringe platform to serve the growing market for biologic therapies.
Analysts’ Opinion of BDX
Many brokerage firms have already submitted their reports for BDX stocks, with Goldman repeating the rating for BDX by listing it as a “Buy.” The predicted price for BDX in the upcoming period, according to Goldman is $274 based on the research report published on May 30, 2024 of the current year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see BDX reach a price target of $305. The rating they have provided for BDX stocks is “Outperform” according to the report published on July 24th, 2023.
Morgan Stanley gave a rating of “Overweight” to BDX, setting the target price at $295 in the report published on May 30th of the previous year.
BDX Trading at -1.31% from the 50-Day Moving Average
After a stumble in the market that brought BDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.07% of loss for the given period.
Volatility was left at 1.61%, however, over the last 30 days, the volatility rate increased by 1.94%, as shares sank -1.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.57% upper at present.
During the last 5 trading sessions, BDX fell by -0.90%, which changed the moving average for the period of 200-days by -1.94% in comparison to the 20-day moving average, which settled at $236.03. In addition, Becton Dickinson & Co. saw -5.02% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BDX starting from BURZIK CATHERINE M, who proposed sale 400 shares at the price of $235.78 back on Sep 16 ’24. After this action, BURZIK CATHERINE M now owns shares of Becton Dickinson & Co., valued at $94,312 using the latest closing price.
Spoerel Thomas J, the SVP,Controller&Chief Acct Off of Becton Dickinson & Co., sale 300 shares at $239.31 during a trade that took place back on Jun 10 ’24, which means that Spoerel Thomas J is holding 1,976 shares at $71,793 based on the most recent closing price.
Stock Fundamentals for BDX
Current profitability levels for the company are sitting at:
- 0.12 for the present operating margin
- 0.42 for the gross margin
The net margin for Becton Dickinson & Co. stands at 0.07. The total capital return value is set at 0.05. Equity return is now at value 5.63, with 2.69 for asset returns.
Based on Becton Dickinson & Co. (BDX), the company’s capital structure generated 0.43 points at debt to capital in total, while cash flow to debt ratio is standing at 0.2. The debt to equity ratio resting at 0.75. The interest coverage ratio of the stock is 8.82.
Currently, EBITDA for the company is 4.71 billion with net debt to EBITDA at 3.58. When we switch over and look at the enterprise to sales, we see a ratio of 4.12. The receivables turnover for the company is 7.64for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.85.
Conclusion
In conclusion, Becton Dickinson & Co. (BDX) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
